Alendronate 70 mg Once Weekly and alendronate 10 mg Once Daily preference study in postmenopausal women with osteoporosis.

被引：0

作者：

Palmisano, J

Lewiecki, EM

Rosen, C

Bockman, RS

Vanaman, LK

Smith, M

Wang, L

Yates, J

机构：

[1] Merck & Co Inc, W Point, PA USA

[2] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA

[3] Maine Ctr Osteoporosis, Bangor, ME USA

[4] Hosp Special Surg, New York, NY 10021 USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2001年 / 16卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S404 / S404

页数：1

共 50 条

[31] Patient compliance and preference of alendronate's once weekly administration in comparison with all daily treatments for osteoporosis in postmenopausal women
Sarakiotis, A
Sarpakis, A
Karanikolas, G
Kaltsas, T
Mixalaki, A
Sfountouris, X
Banavas, K
Marketos, G
Voudouris, K
Georgiadis, AE
OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S95 - S95
[32] Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study
Shinji Uchida
Tadaaki Taniguchi
Takafumi Shimizu
Taro Kakikawa
Kotoba Okuyama
Masahiko Okaniwa
Hironori Arizono
Koichi Nagata
Arthur C. Santora
Masataka Shiraki
Masao Fukunaga
Tatsushi Tomomitsu
Yasuo Ohashi
Toshitaka Nakamura
Journal of Bone and Mineral Metabolism, 2005, 23 : 382 - 388
[33] Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study
Uchida, S
Taniguchi, T
Shimizu, T
Kakikawa, T
Okuyama, K
Okaniwa, M
Arizono, H
Nagata, K
Santora, AC
Shiraki, M
Fukunaga, M
Tomomitsu, T
Ohashi, Y
Nakamura, T
JOURNAL OF BONE AND MINERAL METABOLISM, 2005, 23 (05) : 382 - 388
[34] Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis (vol 20, pg 2031, 2004)
Sebba, AI
Bonnick, SL
Kagan, R
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (02) : 325 - 325
[35] Therapeutic equivalence of alendronate (ALN) 35-mg once weekly (OW) and 5-mg daily (D) in the prevention of postmenopausal osteoporosis
Luckey, M
Insogna, K
Gilchrist, N
Bone, H
Davie, M
De Villiers, T
Orloff, J
Santora, A
Wu, M
Yates, J
OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S209 - S209
[36] Efficacy, safety and tolerability of once weekly (80mg vs 160mg) oral alendronate over 2 years in postmenopausal osteoporosis.
Brown, JP
Banville, C
Jean, S
Drake, WL
Kendler, DL
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S375 - S375
[37] The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis
Yuxiang Yan
Wei Wang
Hanmin Zhu
Mei Li
Jianli Liu
Bangyao Luo
Haibao Xie
Guangjian Zhang
Fuobao Li
Journal of Bone and Mineral Metabolism, 2009, 27 : 471 - 478
[38] The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis
Yan, Yuxiang
Wang, Wei
Zhu, Hanmin
Li, Mei
Liu, Jianli
Luo, Bangyao
Xie, Haibao
Zhang, Guangjian
Li, Fuobao
JOURNAL OF BONE AND MINERAL METABOLISM, 2009, 27 (04) : 471 - 478
[39] Patient preference for once-monthly lbandronate compared with weekly alendronate in postmenopausal osteoporosis
Seidman, Larry S.
Kornowski, Anne
Devas, Vipul
Masanauskaite, Daiva
Emkey, Ron
OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 24S - 25S
[40] Patient complience and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women
Baroutsou, B
Babiolakis, DDB
Stamatiadou, AAS
Andronis, CCA
Piskontaki, IIP
Xristogiannis, FX
Kousta, EEK
Athanasio, IIA
Spanoudis, DDS
Basilakis, R
Voudouris, KKV
Georgiadis, AAG
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 455 - 456

← 1 2 3 4 5 →